Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

Open access
Bhoori, Sherrie, Rossi, Roberta Elisa, Citterio, Davide, Mazzaferro, Vincenzo·2020·The Lancet Gastroenterology & Hepatology

Abstract

Coronavirus disease 2019 (COVID-19) is a public health emergency and a pandemic of international concern. Italy has witnessed, in the past month, an unexpectedly high rate of infection, with more than 100 000 patients testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a case-fatality rate close to 10% (as of March 31, 2020) and therefore faces a worse scenario than in China, where the disease was first reported. Data on COVID-19 in liver transplant patients are scarce. We report the experience in our transplant centre, in the midst of the current outbreak in Lombardy, Italy (10 million inhabitants; 25 124 ascertained infections, and 7199 virus-related deaths as of March 31, 2020). Three of our 111 long-term liver transplant survivors (transplanted more than 10 years ago) have died in the past 3 weeks (between March 5 and March 18) following severe COVID-19 disease. All three were male, older than 65 years, receiving antihypertensive drugs, overweight (BMI >28 kg/m2), with hyperlipidaemia, and diabetes (median HbA1c of 6·9%). The post-transplant course had been uneventful for all three patients, and their immunosuppressive regimen had been gradually tapered off, with very low trough concentrations of calcineurin inhibitors (two patients receiving ciclosporin [28 and 35 ng/mL, respectively] and one receiving tacrolimus [2·1 ng/mL]). All three patients died after admission to hospital for community-acquired pneumonia, and were in need of supplementary oxygen at admission but rapidly developed severe respiratory distress syndrome that required mechanical ventilation. The patients died between 3 and 12 days after the onset of pneumonia; all three patients had tested positive for SARS-CoV-2 by nasopharyngeal swabs. By contrast, three of our 40 recently transplanted (ie, within the past 2 years) patients have tested SARS-CoV-2 positive, and although quarantined, are all experiencing an uneventful course of disease. Available data regarding COVID-19 suggest that tissue damage might be mediated by a direct virus-induced cytopathogenic effect or could be due to an immunomediated inflammatory response to the virus. Whether liver transplant recipients are more susceptible to SARS-CoV-2 infection is a matter of concern, but so far there have been no specific recommendations from major societies. A case series from Italy showed that children who had received liver transplants, despite being immunosuppressed, were not at increased risk of severe pulmonary disease compared with the general population. Al l three COVID-19-related deaths observed in our centre were long-term patients on minimal immunosuppressive regimens, rather than recently transplanted, fully immunosuppressed patients. We examined clinical and demographic data of our patients (table). In keeping with the paediatric data, immunosuppression did not seem to increase the risk of severe COVID-19 disease. Given that a reactive innate immune response might be responsible for severe clinical manifestations, immunosuppression might be protective, although this needs further clarification. Conversely, the presence of metabolic-related comorbidities, which are known to increase with time since transplant, might be associated with an increased risk of severe COVID-19 disease. However, the number of COVID-19related deaths in our series is small, and these observations can only be considered preliminary. Post-transplant metabolic complications (eg, arterial hyper tension, chronic renal insufficiency, diabetes, hyperlipidaemia, and weight gain) might outweigh immuno suppression as a risk factor for development of severe COVID-19 disease in patients who have received liver transplants, in line with data from China, which suggest that comorbidities are associated with a worse prognosis. Of these metabolic complications, diabetes might be of particular concern, given its high prevalence (20–40%) in patients undergoing solid organ transplantation. Notably, a comparison of the 3% COVID-19-associated mortality observed in our long-term transplant recipients with the 10% case-fatality rate noted in Italy at present is difficult, since the case-fatality rate is known to be biased because nasopharyngeal swabbing is only done in highly Published Online April 9, 2020 https://doi.org/10.1016/ S2468-1253(20)30116-3

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(20)30116-3

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 258

Metadata

Authors
Bhoori, S., Rossi, R. E., Citterio, D., & Mazzaferro, V.
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2020-06
Volume
5
Issue
6
Pages
532-533
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
OpenAlex
W3016139359
Cited by
258
References
6
FWCI
51.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. https://app.cochat.ai/papers/10.1016/s2468-1253(20)30116-3
The paper
Bhoori, S., Rossi, R. E., Citterio, D., & Mazzaferro, V. (2020). COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(20)30116-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.